ProQR Therapeutics N.V. Announces Pricing of Public Offering

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE)

Overview:

ProQR Therapeutics N.V. (Nasdaq: PRQR) has recently announced the pricing of its underwritten public offering of 18,000,000 ordinary shares. The Offering, priced at $3.50 per share, is expected to generate total gross proceeds of $63.0 million. This move comes as part of ProQR’s commitment to advancing groundbreaking RNA therapies utilizing its Axiomer™ RNA editing technology platform.

Details of the Offering:

ProQR is offering all 18,000,000 ordinary shares in the public offering, with the potential for an additional 2,700,000 shares to be acquired by the underwriters within a 30-day option period. The public offering price of $3.50 per share will contribute to the funds raised, with deductions for underwriting discounts, commissions, and other related expenses.

ProQR’s innovative approach to RNA therapies has positioned the company as a leader in the industry, with a focus on transforming lives through cutting-edge technology. The public offering signifies a significant milestone for ProQR as it continues to drive innovation and make a difference in the lives of patients worldwide.

Effect on Individuals:

As an individual investor, the pricing of ProQR’s public offering may present an opportunity to participate in the company’s growth potential. By acquiring shares at the offering price, investors have the chance to support ProQR’s mission of advancing RNA therapies and potentially benefit from any future success and value appreciation.

Effect on the World:

ProQR’s public offering and the funds raised through the sale of ordinary shares have the potential to accelerate the development of RNA therapies and contribute to advancements in the field of genetic medicine. This could lead to the creation of innovative treatment options for a wide range of genetic disorders, ultimately impacting the global healthcare landscape and improving patient outcomes on a larger scale.

Conclusion:

The pricing of ProQR Therapeutics N.V.’s public offering marks a significant step forward in advancing RNA therapies and driving transformative change in the biotechnology sector. As the company continues to harness the power of its proprietary Axiomer™ RNA editing technology platform, the potential for groundbreaking developments and positive impact on individuals and the world at large remains promising.